Abstract
Objective: To investigate the expressions of eNOS3 and Ve-cadherin at the first week of reperfused acute myocardial infarction (AMI). Methods:16 of mini-swines (20 to 30 Kg) were randomly assigned to the sham-operated group and the AMI group. Pathologic myocardial tissue was collected at 7-day of LAD reperfusion and assessed by immunofluorescence and laser co-focus microscope scan, in-situ hybridization, real-time quantitative polymerase chain reaction and western blot. Results: At 7-day of reperfusion, the eNOS3 mRNA and protein expressions in the infarcted and marginal areas were lower than those in the normal area and sham-operated area (all P < 0.05), similarly the infarcted and marginal areas had lower Ve-cadherin mRNA expression than the normal area and the sham-operated area (all P < 0.05), and Ve-cadherin protein expression was lower in the infarcted area compared with the marginal area, the normal area and the sham-operated area (all P < 0.05). Conclusion: Lowexpressions of eNOS3 and Ve-cadherin in the salvaged sub-healthy microvascular endothelium of infarcted and marginal areas suggest that endothelial system is impaired at 7-day of reperfused acute myocardial infarction.
Cardiovascular & Hematological Disorders-Drug Targets
Title: Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction
Volume: 9 Issue: 2
Author(s): Sheng Kang, Yue-jin Yang, Qing-zhi Wang, Yue Li, Yi Tian and Yu-tong Cheng
Affiliation:
Abstract: Objective: To investigate the expressions of eNOS3 and Ve-cadherin at the first week of reperfused acute myocardial infarction (AMI). Methods:16 of mini-swines (20 to 30 Kg) were randomly assigned to the sham-operated group and the AMI group. Pathologic myocardial tissue was collected at 7-day of LAD reperfusion and assessed by immunofluorescence and laser co-focus microscope scan, in-situ hybridization, real-time quantitative polymerase chain reaction and western blot. Results: At 7-day of reperfusion, the eNOS3 mRNA and protein expressions in the infarcted and marginal areas were lower than those in the normal area and sham-operated area (all P < 0.05), similarly the infarcted and marginal areas had lower Ve-cadherin mRNA expression than the normal area and the sham-operated area (all P < 0.05), and Ve-cadherin protein expression was lower in the infarcted area compared with the marginal area, the normal area and the sham-operated area (all P < 0.05). Conclusion: Lowexpressions of eNOS3 and Ve-cadherin in the salvaged sub-healthy microvascular endothelium of infarcted and marginal areas suggest that endothelial system is impaired at 7-day of reperfused acute myocardial infarction.
Export Options
About this article
Cite this article as:
Kang Sheng, Yang Yue-jin, Wang Qing-zhi, Li Yue, Tian Yi and Cheng Yu-tong, Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction, Cardiovascular & Hematological Disorders-Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187152909788488663
DOI https://dx.doi.org/10.2174/187152909788488663 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Host Stress and Virulence Expression in Intestinal Pathogens: Development of Therapeutic Strategies Using Mice and C. elegans
Current Pharmaceutical Design Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Intracellular Calcium Homeostasis and Kidney Disease
Current Medicinal Chemistry Patented Techniques for the Extraction and Isolation of Secoisolariciresinol Diglucoside from Flaxseed
Recent Patents on Food, Nutrition & Agriculture NF-κB as a Therapeutic Target for Transcription Factor Decoy Strategy in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Allergic Contact Dermatitis: Novel Mechanisms and Therapeutic Perspectives
Current Drug Metabolism On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Antioxidant Therapy in Critically Septic Patients
Current Drug Targets Biochemical and Pharmacologic Heterogeneity in Low Molecular Weight Heparins. Impact on the Therapeutic Profile
Current Pharmaceutical Design Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design 2015 Update of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research to Clinical Management
Current Pharmaceutical Design Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants
Current Neuropharmacology Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Topical Delivery of Antioxidants
Current Drug Delivery Anti-Atherosclerotic Molecules Targeting Oxidative Stress and Inflammation
Current Pharmaceutical Design Adipose Tissue Derived Stem Cells Secretome: Soluble Factors and Their Roles in Regenerative Medicine
Current Stem Cell Research & Therapy